MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
16.66
-0.19 (-1.13%)
At close: Apr 28, 2026, 4:00 PM EDT
16.76
+0.10 (0.59%)
After-hours: Apr 28, 2026, 7:33 PM EDT
MLTX Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for MLTX stock have an average target of 27.5, with a low estimate of 5.00 and a high estimate of 70. The average target predicts an increase of 65.07% from the current stock price of 16.66.
Analyst Consensus: Buy
* Price targets were last updated on Mar 30, 2026.
Analyst Ratings
The average analyst rating for MLTX stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 6 | 6 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 2 | 2 | 2 | 2 |
| Total | 9 | 9 | 9 | 10 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +80.07% | Mar 30, 2026 |
| Wolfe Research | Wolfe Research | Sell → Buy Upgrades $12 → $24 | Sell → Buy | Upgrades | $12 → $24 | +44.06% | Mar 23, 2026 |
| Rothschild & Co | Rothschild & Co | Hold → Strong Buy Upgrades $12 → $40 | Hold → Strong Buy | Upgrades | $12 → $40 | +140.10% | Mar 19, 2026 |
| Clear Street | Clear Street | Strong Buy Maintains $45 → $70 | Strong Buy | Maintains | $45 → $70 | +320.17% | Mar 11, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | -21.97% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
20.71M
EPS This Year
-3.74
from -3.53
EPS Next Year
-3.71
from -3.74
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 43.6M | ||||||
| Avg | n/a | 20.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.79 | -2.73 | ||||||
| Avg | -3.74 | -3.71 | ||||||
| Low | -4.23 | -5.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.